Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
PENICILLAMINE vs CHEMET
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Chelates heavy metals (copper, mercury, lead, arsenic) forming soluble complexes excreted renally; also reduces cystine formation in cystinuria by disulfide exchange; immunosuppressive effects via inhibition of T-cell function and collagen synthesis.
Chelates heavy metals, particularly lead, mercury, and arsenic, by forming soluble complexes that are excreted renally. Acts as an antidote by binding to toxic metals and reducing their tissue concentrations.
Wilson's disease,Cystinuria,Rheumatoid arthritis,Lead poisoning,Mercury poisoning,Arsenic poisoning
Treatment of acute and chronic lead poisoning,Treatment of mercury poisoning,Treatment of arsenic poisoning,Diagnostic chelation challenge test
250-500 mg orally 4 times daily, with a maximum of 2 g/day; for rheumatoid arthritis, initial dose 125-250 mg/day, increase by 125-250 mg every 1-3 months to usual maintenance of 500-750 mg/day in divided doses.
10-20 mg/kg orally every 8 hours for 5 days; maximum single dose 1250 mg.
Terminal half-life: 1.5–2 hours for penicillamine; after chronic dosing, a slower phase (t1/2 ~40 hours) appears due to tissue binding. Clinical context: Dosing interval typically 6–8 hours; accumulation may occur in renal impairment.
Terminal elimination half-life: 1.6–3.5 hours (mean 2.1 h) in adults with normal renal function; prolonged in renal impairment (up to 20 h).
Hepatic metabolism to S-methyl-penicillamine and penicillamine disulfide; also undergoes renal excretion.
Metabolized in liver to disulfide dimers; undergoes enterohepatic circulation; primarily excreted renally as metabolites and unchanged drug.
Renal: ~80% as unchanged drug and metabolites; fecal: ~20% (via biliary elimination).
Renal: 80–90% as unchanged drug and metabolites (primarily as chelated complexes); biliary/fecal: <10%.
~80% bound to plasma proteins, primarily albumin.
Approximately 80% bound to plasma proteins, primarily albumin.
Vd: 0.1–0.2 L/kg; indicates distribution mainly in extracellular fluid and limited tissue penetration, though accumulates in skin and connective tissue.
0.5–0.8 L/kg, indicating distribution mainly in extracellular fluid; limited intracellular penetration.
Oral: 40–70% (variable due to food and metal ions).
20–40% after oral administration due to first-pass metabolism and limited absorption.
Cr Cl >=50 m L/min: no adjustment; Cr Cl 30-49 m L/min: reduce dose by 50%; Cr Cl 10-29 m L/min: reduce dose by 75%; Cr Cl <10 m L/min: avoid use.
GFR 50-80 m L/min: same dose every 12 hours. GFR 10-49 m L/min: same dose every 24 hours. GFR <10 m L/min: same dose every 48 hours.
No specific adjustments recommended; use with caution in severe hepatic impairment.
No specific recommendations; caution in severe hepatic impairment (Child-Pugh C) due to potential toxicity.
For Wilson disease: 250 mg/m²/day orally in divided doses; for cystinuria: 30 mg/kg/day in divided doses; for rheumatoid arthritis: 2.5-5 mg/kg/day, titrated slowly.
Children >1 year: 10-20 mg/kg/dose orally every 8 hours for 5 days; maximum 1250 mg/dose.
Initiate at low end of dosing range; monitor renal function closely; increased risk of hematologic and autoimmune adverse effects.
Consider starting at lower end of dosing range (10 mg/kg) due to potential renal impairment; adjust per renal function.
None explicitly issued by FDA.
None
Bone marrow suppression (leukopenia, thrombocytopenia, aplastic anemia), proteinuria/nephrotic syndrome, autoimmune reactions (myasthenia gravis, Goodpasture's syndrome, lupus-like syndrome), severe skin reactions (toxic epidermal necrolysis), hepatotoxicity, cross-allergenicity with penicillin. Requires monitoring of CBC, urinalysis, liver function.
May cause nephrotoxicity; monitor renal function,May cause hypersensitivity reactions, including fever, rash, and anaphylaxis,Monitor for neutropenia; obtain CBC before and during therapy,Use caution in patients with hepatic impairment or glucose-6-phosphate dehydrogenase (G6PD) deficiency,May chelate essential minerals (e.g., zinc, copper); monitor levels with prolonged use,Not recommended for routine use in asymptomatic lead poisoning with low blood lead levels
History of aplastic anemia or agranulocytosis, severe renal insufficiency, pregnancy (especially first trimester), breastfeeding, hypersensitivity to penicillamine or penicillin.
Hypersensitivity to dimercaprol or any component of the formulation,Hepatic failure (except severe heavy metal poisoning),Concurrent use with iron (increases nephrotoxicity); avoid iron therapy within 24 hours,Pregnancy (if not life-saving indication due to risk of teratogenicity),Peanut allergy (formulation contains peanut oil)
Avoid high-protein meals and dairy products around dosing; they decrease penicillamine absorption. Separate intake from iron supplements, antacids, and zinc by at least 2 hours. For cystinuria, maintain high fluid intake and possibly restrict sodium and methionine-rich foods (e.g., meats, dairy) as part of therapy.
No specific food interactions reported. However, due to gastrointestinal side effects (nausea, vomiting), it is advisable to maintain small, frequent meals. Avoid alcohol.
First trimester: Known teratogen; associated with cutis laxa, congenital hip dislocation, and other skeletal abnormalities. Contraindicated unless treatment for Wilson disease or cystinuria. Second/third trimesters: Risk of fetal connective tissue defects; avoid unless essential.
FDA Pregnancy Category C. First trimester: No adequate studies, but animal studies show fetal resorption at maternally toxic doses, risk cannot be excluded. Second and third trimesters: No specific teratogenicity, but may cause anemia in fetus due to maternal chelation of essential metals. Avoid use unless clearly needed.
Excreted in breast milk; M/P ratio approximately 0.1. Low concentrations are present; however, due to potential adverse effects (e.g., rash, bone marrow suppression), caution is advised. Consider monitoring infant for rash or blood dyscrasias.
No human data on excretion in breast milk. M/P ratio unknown. Caution due to potential for infant exposure and chelation of trace elements; consider benefit-risk. Avoid breastfeeding during therapy and for 2 weeks after last dose.
No specific dose adjustment is recommended based on pharmacokinetic changes alone; however, due to potential teratogenicity, use only when necessary. Therapeutic drug monitoring may be considered to ensure efficacy without excessive toxicity.
No specific dose adjustments recommended for pregnancy. Increased plasma volume in pregnancy may alter pharmacokinetics, but studies not performed. Use lowest effective dose; monitor therapeutic response and toxicity closely.
Penicillamine is a chelating agent used for Wilson disease, cystinuria, and rheumatoid arthritis. Monitor for bone marrow suppression, proteinuria, and autoimmune reactions. Administer on an empty stomach (1 hour before or 2 hours after meals). Avoid concurrent use with gold, antimalarials, or immunosuppressants due to increased toxicity. Discontinue if rash, fever, or lymphadenopathy develop.
Chelation therapy with dimercaprol (CHEMET) should be initiated within 4 hours of arsenic or mercury exposure for maximal efficacy. Administer only via deep intramuscular injection, never intravenously. Monitor renal function and urine output closely, as dimercaprol can cause nephrotoxicity. Alkalinize urine to p H 7.5-8.5 to decrease renal precipitation of metal-drug complexes. Use with caution in patients with glucose-6-phosphate dehydrogenase deficiency due to risk of hemolysis. Contraindicated in patients with peanut allergy (vehicle is peanut oil).
Take penicillamine on an empty stomach, at least 1 hour before or 2 hours after meals.,Avoid taking with milk, antacids, or iron supplements as they reduce absorption.,Report any unexplained bruising, bleeding, sore throat, or fever immediately.,Watch for signs of proteinuria (foamy urine) or hematuria (blood in urine).,Do not stop abruptly; dose tapering is required.,Use effective contraception; penicillamine can cause fetal harm.
This medication is given as a shot into a muscle, usually in the buttock. It may cause pain at the injection site.,You may experience a metallic taste, nausea, vomiting, headache, or burning sensation in the mouth or throat.,Drink plenty of fluids unless otherwise instructed to help flush metals from your body.,Avoid alcohol during treatment and for at least 48 hours after the last dose.,Report any signs of allergic reaction (rash, itching, difficulty breathing) or dark urine immediately.
"Almasilate, an aluminum-containing antacid, can adsorb penicillamine in the gastrointestinal tract, forming an insoluble complex that reduces penicillamine absorption. This leads to decreased serum concentrations of penicillamine, potentially diminishing its therapeutic effect in diseases such as rheumatoid arthritis or Wilson's disease. Clinically, this interaction may result in loss of disease control or require dose adjustments."
"Calcium carbonate, a common antacid and calcium supplement, chelates with penicillamine in the gastrointestinal tract, forming an insoluble complex that reduces penicillamine absorption. This interaction significantly decreases the bioavailability and serum concentration of penicillamine, potentially compromising its therapeutic efficacy in treating conditions such as rheumatoid arthritis or Wilson's disease. Clinical outcomes may include loss of disease control or increased disease activity, particularly if the drugs are taken concomitantly."
"Concomitant administration of penicillamine and teriflunomide may significantly increase the serum concentration of teriflunomide, primarily due to penicillamine's inhibition of the organic anion transporter 3 (OAT3)-mediated renal elimination of teriflunomide. Elevated teriflunomide levels heighten the risk of dose-dependent adverse effects, including hepatotoxicity, peripheral neuropathy, and immunosuppression. This interaction warrants careful monitoring and potential dose adjustment to avoid toxicity."
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about PENICILLAMINE vs CHEMET, answered by our medical review team.
PENICILLAMINE is a Chelating Agent that works by Chelates heavy metals (copper, mercury, lead, arsenic) forming soluble complexes excreted renally; also reduces cystine formation in cystinuria by disulfide exchange; immunosuppressive effects via inhibition of T-cell function and collagen synthesis.. CHEMET is a Chelating agent that works by Chelates heavy metals, particularly lead, mercury, and arsenic, by forming soluble complexes that are excreted renally. Acts as an antidote by binding to toxic metals and reducing their tissue concentrations.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between PENICILLAMINE and CHEMET depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of PENICILLAMINE is: 250-500 mg orally 4 times daily, with a maximum of 2 g/day; for rheumatoid arthritis, initial dose 125-250 mg/day, increase by 125-250 mg every 1-3 months to usual maintenance of 500-750 mg/day in divided doses.. The standard adult dose of CHEMET is: 10-20 mg/kg orally every 8 hours for 5 days; maximum single dose 1250 mg.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between PENICILLAMINE and CHEMET in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. PENICILLAMINE is classified as Category C. First trimester: Known teratogen; associated with cutis laxa, congenital hip dislocation, and other skeletal abnormalities. Contraindicated unless treatment for Wilson disease or c. CHEMET is classified as Category C. FDA Pregnancy Category C. First trimester: No adequate studies, but animal studies show fetal resorption at maternally toxic doses, risk cannot be excluded. Second and third trimes. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.